MarketCap
Facebook
X
Telegram
Opthea Limited Market Cap | OPT
As of September 14, 2026 Opthea Limited has a market cap of $ 1.2 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Opthea Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 2.11 B | 2.24 B | 2.87 B | - | 277 K | 3.63 M | 207 K | 150 K | 4.1 M | 1.93 M | 3.51 M | 40.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.87 B | 150 K | 661 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
385 M | $ 5.65 | 6.11 % | $ 692 M |  USA |
 |
Фармсинтез
LIFE
|
2 B | - | - | - |  Russia |
 |
AbbVie
ABBV
|
400 B | $ 261.61 | 1.7 % | $ 463 B | USA |
 |
AbCellera Biologics
ABCL
|
962 M | $ 11.07 | 1.61 % | $ 3.31 B |  Canada |
 |
Agenus
AGEN
|
97.8 M | $ 7.08 | 2.07 % | $ 211 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
2.55 B | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
27 M | - | -14.46 % | $ 27.9 M | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
427 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
2.05 B | - | -15.15 % | $ 60.3 M | Britain |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
252 M | $ 5.38 | 0.28 % | $ 285 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
1.63 B | $ 33.41 | 0.16 % | $ 1.94 B | USA |
 |
Adagene
ADAG
|
224 M | $ 3.3 | 2.94 % | $ 195 M |  China |
 |
iTeos Therapeutics
ITOS
|
293 M | - | - | $ 411 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
3.19 M | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Adaptive Biotechnologies Corporation
ADPT
|
2.48 B | $ 24.7 | 2.05 % | $ 3.75 B | USA |
 |
Akouos
AKUS
|
184 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
548 M | - | -0.23 % | $ 916 M | USA |
 |
BioXcel Therapeutics
BTAI
|
15.4 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
13 M | $ 23.52 | 458.67 % | $ 98.9 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
26 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
847 M | $ 5.13 | 0.1 % | $ 983 M | Canada |
 |
ADC Therapeutics SA
ADCT
|
139 M | $ 1.09 | 2.35 % | $ 139 M |  Schweiz |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
4.13 M | - | 17.91 % | $ 11.1 M | USA |
 |
Adial Pharmaceuticals
ADIL
|
1.31 M | $ 5.03 | 2.65 % | $ 3.36 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
3.65 B | $ 27.54 | 0.04 % | $ 4.64 B | USA |
 |
AIM ImmunoTech
AIM
|
1.13 M | $ 0.22 | 1.52 % | $ 356 K | USA |
 |
ADMA Biologics
ADMA
|
3.78 B | $ 9.18 | 0.16 % | $ 2.19 B | USA |
 |
Axcella Health
AXLA
|
25 M | - | -16.42 % | $ 249 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
17 M | - | 57.95 % | $ 12.8 M | USA |
 |
Atreca
BCEL
|
49 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
78.6 M | - | -74.18 % | $ 955 K | USA |
 |
Achieve Life Sciences
ACHV
|
126 M | $ 7.15 | 1.27 % | $ 312 M | USA |
 |
Baudax Bio
BXRX
|
779 K | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
49.1 M | - | -10.95 % | $ 876 K | USA |
 |
CymaBay Therapeutics
CBAY
|
3.43 B | - | - | $ 3.45 B | USA |
 |
Codiak BioSciences
CDAK
|
243 M | - | -55.98 % | $ 2.15 M | USA |
 |
ChemoCentryx
CCXI
|
1.88 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
423 M | - | - | $ 789 M | USA |
|
Cerevel Therapeutics Holdings
CERE
|
6.68 B | - | - | $ 7.29 B | USA |
 |
AC Immune SA
ACIU
|
287 M | $ 2.67 | 2.6 % | $ 269 M | Schweiz |
 |
Akebia Therapeutics
AKBA
|
334 M | $ 1.0 | 5.6 % | $ 257 M | USA |
 |
Alector
ALEC
|
247 M | $ 2.17 | 1.64 % | $ 224 M | USA |
 |
Aligos Therapeutics
ALGS
|
65.9 M | $ 5.05 | 0.96 % | $ 49.9 M | USA |